Antibody drug conjugates: Progress, pitfalls, and promises.

Publication Title

Human antibodies

Authors

Anubhab Mukherjee, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, Pacific Neuroscience Institute, Providence Saint John's Health Center, Santa Monica, CA-90404, USAFollow
Ariana K Waters, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, Pacific Neuroscience Institute, Providence Saint John's Health Center, Santa Monica, CA-90404, USAFollow
Ivan Babic, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, Pacific Neuroscience Institute, Providence Saint John's Health Center, Santa Monica, CA-90404, USA
Elmar Nurmemmedov, John Wayne Cancer Institute & Pacific Neuroscience Institute at Providence Saint John's Health Center, Santa Monica, CA 90404, USA.Follow
Mark C Glassy
Santosh Kesari, Department of Translational Neuro-Oncology and Neurotherapeutics, John Wayne Cancer Institute at Providence Saint John's Health CenterFollow
Venkata Mahidhar Yenugonda, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, Pacific Neuroscience Institute, Providence Saint John's Health Center, Santa Monica, CA-90404, USAFollow

Document Type

Article

Publication Date

9-7-2018

Abstract

Antibody drug conjugates (ADC's) represent a promising and an efficient strategy for targeted cancer therapy. Comprised of a monoclonal antibody, a cytotoxic drug, and a linker, ADC's offer tumor selectively, reduced toxicity, and improved stability in systemic circulation. Recent approvals of two ADC's have led to a resurgence in ADC research, with more than 60 ADC's under various stages of clinical development. The therapeutic success of future ADCs is dependent on adherence to key requirements of their design and careful selection of the target antigen on cancer cells. Here we review the main components in the design of antibody drug conjugates, improvements made, and lessons learned over two decades of research, as well as the future of third generation ADCs.

Area of Special Interest

Cancer

Specialty/Research Institute

Oncology

Specialty/Research Institute

Pharmacy